Logo image of GDTC

CYTOMED THERAPEUTICS LTD (GDTC) Stock Fundamental Analysis

USA - NASDAQ:GDTC - SGXZ17669631 - Common Stock

1.8 USD
-0.31 (-14.69%)
Last: 11/6/2025, 12:13:19 PM
Fundamental Rating

3

Taking everything into account, GDTC scores 3 out of 10 in our fundamental rating. GDTC was compared to 534 industry peers in the Biotechnology industry. While GDTC seems to be doing ok healthwise, there are quite some concerns on its profitability. GDTC is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

GDTC had negative earnings in the past year.
GDTC had a negative operating cash flow in the past year.
GDTC had negative earnings in each of the past 5 years.
GDTC had a negative operating cash flow in each of the past 5 years.
GDTC Yearly Net Income VS EBIT VS OCF VS FCFGDTC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 -1M -2M -3M -4M

1.2 Ratios

With a decent Return On Assets value of -28.08%, GDTC is doing good in the industry, outperforming 69.66% of the companies in the same industry.
GDTC's Return On Equity of -30.14% is fine compared to the rest of the industry. GDTC outperforms 77.15% of its industry peers.
Industry RankSector Rank
ROA -28.08%
ROE -30.14%
ROIC N/A
ROA(3y)-42.33%
ROA(5y)-41.37%
ROE(3y)-215.47%
ROE(5y)-218.97%
ROIC(3y)N/A
ROIC(5y)N/A
GDTC Yearly ROA, ROE, ROICGDTC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 -100 -200 -300 -400 -500

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for GDTC so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
GDTC Yearly Profit, Operating, Gross MarginsGDTC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023

More info and screens

6

2. Health

2.1 Basic Checks

Compared to 1 year ago, GDTC has about the same amount of shares outstanding.
Compared to 1 year ago, GDTC has an improved debt to assets ratio.
GDTC Yearly Shares OutstandingGDTC Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2M 4M 6M 8M 10M
GDTC Yearly Total Debt VS Total AssetsGDTC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2M 4M 6M 8M 10M

2.2 Solvency

GDTC has an Altman-Z score of 23.82. This indicates that GDTC is financially healthy and has little risk of bankruptcy at the moment.
GDTC has a better Altman-Z score (23.82) than 91.76% of its industry peers.
A Debt/Equity ratio of 0.04 indicates that GDTC is not too dependend on debt financing.
GDTC has a Debt to Equity ratio (0.04) which is in line with its industry peers.
Industry RankSector Rank
Debt/Equity 0.04
Debt/FCF N/A
Altman-Z 23.82
ROIC/WACCN/A
WACCN/A
GDTC Yearly LT Debt VS Equity VS FCFGDTC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 0 5M 10M

2.3 Liquidity

A Current Ratio of 21.54 indicates that GDTC has no problem at all paying its short term obligations.
The Current ratio of GDTC (21.54) is better than 95.51% of its industry peers.
GDTC has a Quick Ratio of 21.54. This indicates that GDTC is financially healthy and has no problem in meeting its short term obligations.
With an excellent Quick ratio value of 21.54, GDTC belongs to the best of the industry, outperforming 95.51% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 21.54
Quick Ratio 21.54
GDTC Yearly Current Assets VS Current LiabilitesGDTC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2M 4M 6M 8M 10M

More info and screens

3

3. Growth

3.1 Past

GDTC shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 59.91%, which is quite impressive.
EPS 1Y (TTM)59.91%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%57.52%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, GDTC will show a quite strong growth in Earnings Per Share. The EPS will grow by 16.02% on average per year.
The Revenue is expected to grow by 9.59% on average over the next years. This is quite good.
EPS Next Y42.31%
EPS Next 2Y16.02%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year31.87%
Revenue Next 2Y9.59%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

GDTC Yearly Revenue VS EstimatesGDTC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2025 100K 200K 300K 400K 500K
GDTC Yearly EPS VS EstimatesGDTC Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 -0.05 -0.1 -0.15 -0.2 -0.25

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for GDTC. In the last year negative earnings were reported.
Also next year GDTC is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
GDTC Price Earnings VS Forward Price EarningsGDTC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
GDTC Per share dataGDTC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 0.6

4.3 Compensation for Growth

GDTC's earnings are expected to grow with 16.02% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y16.02%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for GDTC!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CYTOMED THERAPEUTICS LTD

NASDAQ:GDTC (11/6/2025, 12:13:19 PM)

1.8

-0.31 (-14.69%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-05 2025-05-05
Earnings (Next)11-14 2025-11-14
Inst Owners0.43%
Inst Owner ChangeN/A
Ins Owners12.77%
Ins Owner Change0%
Market Cap21.01M
Revenue(TTM)N/A
Net Income(TTM)-3063200
Analysts82.86
Price Target5.1 (183.33%)
Short Float %2.79%
Short Ratio1.17
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 2.7
P/tB 2.7
EV/EBITDA N/A
EPS(TTM)-0.2
EYN/A
EPS(NY)-0.13
Fwd EYN/A
FCF(TTM)-0.23
FCFYN/A
OCF(TTM)-0.17
OCFYN/A
SpS0
BVpS0.67
TBVpS0.67
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -28.08%
ROE -30.14%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-42.33%
ROA(5y)-41.37%
ROE(3y)-215.47%
ROE(5y)-218.97%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.04
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 275.74%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 21.54
Quick Ratio 21.54
Altman-Z 23.82
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)103.86%
Cap/Depr(5y)210.93%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)59.91%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%57.52%
EPS Next Y42.31%
EPS Next 2Y16.02%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year31.87%
Revenue Next 2Y9.59%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y15.33%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-37.5%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-63.78%
OCF growth 3YN/A
OCF growth 5YN/A

CYTOMED THERAPEUTICS LTD / GDTC FAQ

Can you provide the ChartMill fundamental rating for CYTOMED THERAPEUTICS LTD?

ChartMill assigns a fundamental rating of 3 / 10 to GDTC.


What is the valuation status of CYTOMED THERAPEUTICS LTD (GDTC) stock?

ChartMill assigns a valuation rating of 0 / 10 to CYTOMED THERAPEUTICS LTD (GDTC). This can be considered as Overvalued.


Can you provide the profitability details for CYTOMED THERAPEUTICS LTD?

CYTOMED THERAPEUTICS LTD (GDTC) has a profitability rating of 1 / 10.


Can you provide the expected EPS growth for GDTC stock?

The Earnings per Share (EPS) of CYTOMED THERAPEUTICS LTD (GDTC) is expected to grow by 42.31% in the next year.